542 related articles for article (PubMed ID: 16046206)
1. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite.
Nancollas GH; Tang R; Phipps RJ; Henneman Z; Gulde S; Wu W; Mangood A; Russell RG; Ebetino FH
Bone; 2006 May; 38(5):617-27. PubMed ID: 16046206
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates: mode of action and pharmacology.
Russell RG
Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
4. The relationship between the chemistry and biological activity of the bisphosphonates.
Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Russell RG; Xia Z; Dunford JE; Oppermann U; Kwaasi A; Hulley PA; Kavanagh KL; Triffitt JT; Lundy MW; Phipps RJ; Barnett BL; Coxon FP; Rogers MJ; Watts NB; Ebetino FH
Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates: from bench to bedside.
Russell RG
Ann N Y Acad Sci; 2006 Apr; 1068():367-401. PubMed ID: 16831938
[TBL] [Abstract][Full Text] [Related]
7. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy.
Leu CT; Luegmayr E; Freedman LP; Rodan GA; Reszka AA
Bone; 2006 May; 38(5):628-36. PubMed ID: 16185944
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of action of bisphosphonates: current status.
Roelofs AJ; Thompson K; Gordon S; Rogers MJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
[TBL] [Abstract][Full Text] [Related]
9. Necrotic actions of nitrogen-containing bisphosphonates and their inhibition by clodronate, a non-nitrogen-containing bisphosphonate in mice: potential for utilization of clodronate as a combination drug with a nitrogen-containing bisphosphonate.
Oizumi T; Yamaguchi K; Funayama H; Kuroishi T; Kawamura H; Sugawara S; Endo Y
Basic Clin Pharmacol Toxicol; 2009 May; 104(5):384-92. PubMed ID: 19413658
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates: from the laboratory to the clinic and back again.
Russell RG; Rogers MJ
Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate protonation states, conformations, and dynamics on bone mineral probed by solid-state NMR without isotope enrichment.
Ironside MS; Duer MJ; Reid DG; Byard S
Eur J Pharm Biopharm; 2010 Sep; 76(1):120-6. PubMed ID: 20554022
[TBL] [Abstract][Full Text] [Related]
12. An in vitro assay to measure targeted drug delivery to bone mineral.
Jahnke W; Henry C
ChemMedChem; 2010 May; 5(5):770-6. PubMed ID: 20209564
[TBL] [Abstract][Full Text] [Related]
13. NMR investigations of the static and dynamic structures of bisphosphonates on human bone: a molecular model.
Mukherjee S; Song Y; Oldfield E
J Am Chem Soc; 2008 Jan; 130(4):1264-73. PubMed ID: 18173269
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
15. Determination of bisphosphonate active pharmaceutical ingredients in pharmaceuticals and biological material: a review of analytical methods.
Zacharis CK; Tzanavaras PD
J Pharm Biomed Anal; 2008 Nov; 48(3):483-96. PubMed ID: 18599247
[TBL] [Abstract][Full Text] [Related]
16. Physiology of the aging bone and mechanisms of action of bisphosphonates.
Dominguez LJ; Di Bella G; Belvedere M; Barbagallo M
Biogerontology; 2011 Oct; 12(5):397-408. PubMed ID: 21695491
[TBL] [Abstract][Full Text] [Related]
17. [Bisphosphonates: the molecular targets and mechanisms of action].
Wada S; Kamiya S; Ono K
Clin Calcium; 2005 May; 15(5):819-24. PubMed ID: 15876745
[TBL] [Abstract][Full Text] [Related]
18. Differences between bisphosphonates in binding affinities for hydroxyapatite.
Lawson MA; Xia Z; Barnett BL; Triffitt JT; Phipps RJ; Dunford JE; Locklin RM; Ebetino FH; Russell RG
J Biomed Mater Res B Appl Biomater; 2010 Jan; 92(1):149-55. PubMed ID: 19904734
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of action of the bisphosphonates.
Fleisch H
Medicina (B Aires); 1997; 57 Suppl 1():65-75. PubMed ID: 9567358
[TBL] [Abstract][Full Text] [Related]
20. Anabolic effects of bisphosphonates on peri-implant bone stock.
von Knoch F; Eckhardt C; Alabre CI; Schneider E; Rubash HE; Shanbhag AS
Biomaterials; 2007 Aug; 28(24):3549-59. PubMed ID: 17498799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
